NCT03895996View on ClinicalTrials.gov

Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

June 20, 2019

Primary Completion Date

May 17, 2022

Study Completion Date

December 19, 2023

Conditions
Type 1 Diabetes Mellitus
Interventions
DRUG

AVT001

autologous dendritic cell therapy

OTHER

Placebo

matched placebo

Trial Locations (1)

02215

Joslin Diabetes Center, Harvard Medical School, Boston

Sponsors

Lead Sponsor

Avotres Inc.
All Listed Sponsors
lead

Avotres Inc.

INDUSTRY

NCT03895996 - Safety, Tolerability and Potential Efficacy of AVT001 in Patients With Type 1 Diabetes | Biotech Hunter | Biotech Hunter